Skip to main content
NCBI home page
American Journal of Public Health logoLink to American Journal of Public Health
. 1994 Dec;84(12):1971–1975. doi: 10.2105/ajph.84.12.1971

The types of drugs used by HIV-infected injection drug users in a multistate surveillance project: implications for intervention.

T Diaz 1, S Y Chu 1, R H Byers Jr 1, B S Hersh 1, L Conti 1, C A Rietmeijer 1, E Mokotoff 1, S A Fann 1, D Boyd 1, L Iglesias 1, et al.
PMCID: PMC1615366  PMID: 7998639

Abstract

OBJECTIVES. This study sought to describe the drugs used by drug injectors infected with human immunodeficiency virus (HIV) and to determine factors associated with the primary injection drug used. METHODS. A cross-section of persons 18 years of age or older reported with HIV or acquired immunodeficiency syndrome (AIDS) to local health departments in 11 US states and cities was surveyed. RESULTS. Of 4162 persons interviewed, 1147 (28%) reported ever having injected drugs. Of these 1147 injectors, 72% primarily injected a drug other than heroin. However, the types of drugs injected varied notably by place of residence. Heroin was the most commonly injected drug in Detroit (94%) and Connecticut (48%); cocaine was the most common in South Carolina (64%), Atlanta (56%), Delaware (55%), Denver (46%), and Arizona (44%); speedball was most common in Florida (46%); and amphetamines were most common in Washington (56%). Other determinants of the type of drug primarily injected were often similar by region of residence, except for heroin use. Polysubstance abuse was common; 75% injected more than one type of drug, and 85% reported noninjected drug use. CONCLUSIONS. Preventing the further spread of HIV will require more drug abuse treatment programs that go beyond methadone, address polysubstance abuse, and adapt to local correlates of the primary drug used.

Full text

PDF
1971

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alcabes P., Vlahov D., Anthony J. C. Characteristics of intravenous drug users by history of arrest and treatment for drug use. J Nerv Ment Dis. 1992 Jan;180(1):48–54. doi: 10.1097/00005053-199201000-00010. [DOI] [PubMed] [Google Scholar]
  2. Brown B. S. AIDS and the provision of drug user treatment. Int J Addict. 1990;25(12A):1503–1514. doi: 10.3109/10826089009088557. [DOI] [PubMed] [Google Scholar]
  3. Chaisson R. E., Bacchetti P., Osmond D., Brodie B., Sande M. A., Moss A. R. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA. 1989 Jan 27;261(4):561–565. [PubMed] [Google Scholar]
  4. Cooper J. R. Methadone treatment and acquired immunodeficiency syndrome. JAMA. 1989 Sep 22;262(12):1664–1668. [PubMed] [Google Scholar]
  5. Diaz T., Chu S. Y., Conti L., Nahlen B. L., Whyte B., Mokotoff E., Shields A., Checko P. J., Herr M., Mukhtar Q. Health insurance coverage among persons with AIDS: results from a multistate surveillance project. Am J Public Health. 1994 Jun;84(6):1015–1018. doi: 10.2105/ajph.84.6.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Farley T. A., Cartter M. L., Wassell J. T., Hadler J. L. Predictors of outcome in methadone programs: effect of HIV counseling and testing. AIDS. 1992 Jan;6(1):115–121. doi: 10.1097/00002030-199201000-00016. [DOI] [PubMed] [Google Scholar]
  7. Kozel N. J., Adams E. H. Epidemiology of drug abuse: an overview. Science. 1986 Nov 21;234(4779):970–974. doi: 10.1126/science.3490691. [DOI] [PubMed] [Google Scholar]
  8. Marmor M., Des Jarlais D. C., Cohen H., Friedman S. R., Beatrice S. T., Dubin N., el-Sadr W., Mildvan D., Yancovitz S., Mathur U. Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS. 1987 May;1(1):39–44. [PubMed] [Google Scholar]
  9. Novick D. M., Trigg H. L., Des Jarlais D. C., Friedman S. R., Vlahov D., Kreek M. J. Cocaine injection and ethnicity in parenteral drug users during the early years of the human immunodeficiency virus (HIV) epidemic in New York City. J Med Virol. 1989 Nov;29(3):181–185. doi: 10.1002/jmv.1890290307. [DOI] [PubMed] [Google Scholar]
  10. Schoenbaum E. E., Hartel D., Selwyn P. A., Klein R. S., Davenny K., Rogers M., Feiner C., Friedland G. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med. 1989 Sep 28;321(13):874–879. doi: 10.1056/NEJM198909283211306. [DOI] [PubMed] [Google Scholar]
  11. Schrager L., Friedland G., Feiner C., Kahl P. Demographic characteristics, drug use, and sexual behavior of i.v. drug user with AIDS in Bronx, New York. Public Health Rep. 1991 Jan-Feb;106(1):78–84. [PMC free article] [PubMed] [Google Scholar]
  12. Simpson D. D., Savage L. J., Lloyd M. R. Follow-up evaluation of treatment of drug abuse during 1969 to 1972. Arch Gen Psychiatry. 1979 Jul;36(7):772–780. doi: 10.1001/archpsyc.1979.01780070050005. [DOI] [PubMed] [Google Scholar]
  13. Vlahov D., Anthony J. C., Celentano D., Solomon L., Chowdhury N. Trends of HIV-1 risk reduction among initiates into intravenous drug use 1982-1987. Am J Drug Alcohol Abuse. 1991;17(1):39–48. doi: 10.3109/00952999108992808. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES